|
| 特征 |
电话(n = 25) |
常规治疗(n = 25) |
假定值 |
|
| 性别,女 |
18 (72%) |
12 (48%) |
0.083 |
| 年龄、年 |
56.6+11.9 |
58.7+10.0 |
0.506 |
| 使用华法林的经验 |
|
|
|
| 天真的 |
13 (52%) |
13 (52%) |
1.00 |
| <三个月的经验 |
5 (20%) |
3 (12%) |
0.440 |
| > 3个月经验 |
7 (28%) |
9 (36%) |
0.544 |
| 指示 |
|
|
|
| 心脏瓣膜病 |
6 (24%) |
8 (32%) |
0.529 |
| 机械人工心脏瓣膜 |
2 (8%) |
1 (4%) |
0.552 |
| 心房纤颤 |
14 (56%) |
17 (68%) |
0.382 |
| 深静脉血栓形成 |
8 (32%) |
6 (24%) |
0.529 |
| 肺栓塞 |
0 (0%) |
1 (4%) |
0.312 |
| 并发症 |
|
|
|
| 糖尿病 |
4 (16%) |
5 (20%) |
0.713 |
| 高血压 |
9 (36%) |
15 (60%) |
0.089 |
| 血脂异常 |
7 (28%) |
8 (32%) |
0.758 |
| 缺血性心脏病 |
3 (12%) |
1 (4%) |
0.297 |
| 心脏衰竭 |
5 (20%) |
6 (24%) |
0.123 |
| 慢性肾脏疾病 |
5 (20%) |
6 (24%) |
0.733 |
| 其他人 |
3 (12%) |
2 (8%) |
0.637 |
华法林剂量在放电
(平均+SD) |
18.2±6.7 |
18.1±4.6 |
0.922 |
| 目标INR |
|
|
|
| 2.0 - -3.0 |
23 (92%) |
24 (96%) |
0.552 |
| 2.5 - -3.5 |
2 (8%) |
1 (4%) |
0.552 |
|
|
